Hiroko Shigemi
Impact in
-
- Neurogenesis and neuroplasticity mechanisms
-
- Tryptophan and brain disorders
Papers in
-
- Antifungal resistance and susceptibility 4
- HIV/AIDS drug development and treatment 2
-
- Ubiquitin and proteasome pathways 2
- Co-authors
- Takahiro Yamauchi (12 shared papers)Takanori Ueda (12 shared papers)Kenji Shigemi (2 shared papers)Masako Tsuzuki (1 shared paper)Toshiyuki Kumagai (1 shared paper)Ritsuko Katoh‐Semba (1 shared paper)Noriko Miyazaki (1 shared paper)Futoshi Yoshida (1 shared paper)
- Journals
- Blood (3 papers)BMC Cancer (3 papers)Cancer Science (2 papers)Medicine (1 paper)International Journal of Infectious Diseases (1 paper)
- Partner nations
- JapanUnited StatesChina
In The Last Decade
Hiroko Shigemi
29 papers receiving 358 citations
Peers
Comparison fields: 5 of 82
- Developmental Neuroscience 20
- Biological Psychiatry 11
- Cellular and Molecular Neuroscience 65
- Hematology 34
- Cognitive Neuroscience 55
Countries citing papers authored by Hiroko Shigemi
This map shows the geographic impact of Hiroko Shigemi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroko Shigemi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroko Shigemi more than expected).
Fields of papers citing papers by Hiroko Shigemi
This network shows the impact of papers produced by Hiroko Shigemi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroko Shigemi. The network helps show where Hiroko Shigemi may publish in the future.
Co-authors
The 25 scholars most cited alongside Hiroko Shigemi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 122 | |
| 2 | 2015 | 29 | |
| 3 | 2013 | 26 | |
| 4 | 2020 | 22 | |
| 5 | 1990 | 20 | |
| 6 | 2019 | 15 | |
| 7 | Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells. | 2014 | 15 |
| 8 | 2014 | 12 | |
| 9 | 2014 | 12 | |
| 10 | 2013 | 11 | |
| 11 | 2020 | 11 | |
| 12 | Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. | 2014 | 11 |
| 13 | 2020 | 10 | |
| 14 | 2022 | 10 | |
| 15 | 2019 | 6 | |
| 16 | 2017 | 6 | |
| 17 | 2019 | 5 | |
| 18 | 2023 | 5 | |
| 19 | 2021 | 3 | |
| 20 | 2013 | 2 |
About Hiroko Shigemi
Hiroko Shigemi is a scholar working on Infectious Diseases, Molecular Biology, Epidemiology, Public Health, Environmental and Occupational Health and Hematology, having authored 29 papers that have together received 365 indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (4 papers), Fungal Infections and Studies (3 papers), Ubiquitin and proteasome pathways (2 papers), HIV/AIDS drug development and treatment (2 papers), Vector-borne infectious diseases (2 papers), Acute Lymphoblastic Leukemia research (2 papers), Multiple Myeloma Research and Treatments (2 papers) and Bacterial Identification and Susceptibility Testing (2 papers). The work is most often cited by research in Developmental Neuroscience (20 citations), Biological Psychiatry (11 citations), Cellular and Molecular Neuroscience (65 citations), Hematology (34 citations) and Cognitive Neuroscience (55 citations). Hiroko Shigemi has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Takahiro Yamauchi, Takanori Ueda, Kenji Shigemi, Masako Tsuzuki, Toshiyuki Kumagai, Ritsuko Katoh‐Semba, Noriko Miyazaki, Futoshi Yoshida, Atsuo Nakayama and Yukië Tanaka. Their work appears in journals such as Blood, BMC Cancer, Cancer Science, Medicine and International Journal of Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.